Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma

Head and Neck

Volumn 26, Issue 11, 2004, Pages 977-983

  Ho, Sheng Yow ^a,c   Guo, How Ran ^a   Chen, Helen H W ^a,b   Hsiao, Jenn Ren ^a   Jin, Yin Tai ^a   Tsai, Sen Tien ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c TAINAN SIN LAU HOSPITAL   (Taiwan)

Author keywords

Disease stage; Fas ligand; Lymph node metastasis; Nasopharyngeal carcinoma; Survival

Indexed keywords

FAS LIGAND; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; FAS LIGAND PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TAIWAN; TUMOR MARKERS, BIOLOGICAL;

EID: 8444223227     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20090     Document Type: Article

References (31)

1. De-The G, Ho JHC, Muir CS. Nasopharyngeal carcinoma. In: Evans AS, editor. Viral infections of humans: epidemiology and control. New York: John Wiley & Sons; 1982. p 621-652.
2. Shanmugaratnam K, Chan SH, de-The G, et al. Histopathology of nasopharyngeal carcinoma: correlation with epidemiology, survival rates and other biological characteristics. Cancer 1979;44:1029-1044.
3. Galili U, Klein E, Klein G, Singh Bal I. Activated T lymphocytes in infiltrates and draining lymph nodes of nasopharyngeal carcinoma. Int J Cancer 1980;25:85-89.
4. Hsu MM, Hsu HC, Lui LT. Local immune reaction in nasopharyngeal carcinoma, with special reference to its prognostic evaluation. Head Neck 1989;11:505-510.
5. Zong YS, Zhang CQ, Zhang F, et al. Infiltrating lymphocytes and accessory cells in nasopharyngeal carcinoma. Jpn J Cancer Res 1993;84:900-905.
6. Baker PE, Fahey JV, Munck A. Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol 1981;61:52-61.
7. Robb RJ. The suppressive effect of gangliosides upon IL-2-dependent proliferation as a function of inhibition of IL-2-receptor association. J Immunol 1986;136:971-976.
8. Siepl C, Bodmer S, Frei K, et al. The glioblastoma-derived T-cell suppressor factor/transforming growth factor-beta 2 inhibits T-cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 1988;18: 593-600.
9. O'Connell J, Houston A, Bennett M, O'Sullivan G, Shanahan F. Immune privilege of inflammation? Insight into the Fas ligand enigma. Nature Med 2001;7:271-274.
10. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996;2:1361-1366.
11. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-1366.
12. Mann B, Gratchev A, Bohm C, et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999; 79:1262-1269.
13. Mottolese M, Buglioni S, Bracalenti C, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000;89:127-132.
14. Munakata S, Enomoto T, Tsujimoto M, et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000;82:1446-1452.
15. Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000;82:1211-1217.
16. Tsai ST, Fang SY, Jin YT, Su IJ, Yang BC. Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues. Oral Oncol 1999;35:421-424.
17. Fleming ID, Cooper JS, Henson DE, et al. American Joint Committee on Cancer. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
18. Hsiao JR, Jin YT, Tsai ST. Detection of cell free Epstein-Barr virus in sera from patients with nasopharyngeal carcinoma. Cancer 2002;94:723-729.
19. Cancer Registry Annual Report Republic of China, 1995. Taiwan, ROC: Department of Health, the Executive Yuan; 1998.
20. Sampalo A, Navas G, Medina F, Segundo C, Camara C, Brieva JA. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000;96: 3168-3174.
21. Van Parijs L, Ibraghimov A, Abbas AK. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 1996;4:321-328.
22. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997;94:13862-13867.
23. Nagarkatti N. Tumor derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy. Cancer Immunol Immunother 2000;49:46-55.
24. Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys 2001;50:1181-1189.
25. Tsai MH, Chow KC, Lin TY, Yeh SP, Hsueh CY, Chi KH. Expression of Fas ligand in patients with evident skull base involvement of nasopharyngeal carcinoma. Oncol Rep 2002;9:247-251.
26. Chang JT, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2000;54:135-142.
27. Volm M, Koomagi R. Relevance of proliferative and proapoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 2000;82:1747-1754.
28. Cui H, Sherr DH, el-Khatib M, et al. Regulation of T-cell death genes: selective inhibition of Fas-L but not Fas-mediated function. Cell Immunol 1996;167:276-284.
29. Yakes FM, Wamil BD, Sun F, Yan HP, Carter CE, Hellerqvist CG. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. Cancer Res 2000; 60:5740-5746.
30. Hong RL, Ting LL, Ko JY, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:4305-4313.
31. Cheng S, Jian JJ, Tsai SY, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000;48:1323-1330.